Health disparities and impact on outcomes in children with primary central nervous system solid tumors

Mary T Austin1,2,3, Emma Hamilton3, Denna Zebda3

  • 1Department of Pediatrics, Children's Cancer Hospital at The University of Texas MD Anderson Cancer Center;

Insights

Racial and ethnic disparities impact pediatric patients with central nervous system (CNS) solid tumors, leading to advanced-stage disease at diagnosis. Survival rates are significantly worse for Hispanic and Black children and those from lower socioeconomic backgrounds.

Area of Science:

  • Pediatric Oncology
  • Health Disparities Research
  • Neuro-oncology

Background:

  • Health disparities are well-documented in adult cancer care, affecting access, early detection, and survival.
  • Limited research exists on how these disparities influence pediatric malignancies, particularly central nervous system (CNS) solid tumors.

Purpose of the Study:

  • To investigate the impact of racial/ethnic and socioeconomic factors on disease presentation and outcomes in pediatric CNS solid tumors.
  • To analyze the association between geographic distance to treatment centers and disease stage or survival.

Main Methods:

  • Analysis of 2421 pediatric patients (≤18 years) diagnosed with primary CNS solid tumors between 1995-2009 from the Texas Cancer Registry.
  • Utilized geocoded data for driving distance to treatment centers and US Census data for socioeconomic status (SES) determination.
  • Employed logistic regression for disease stage analysis and Cox regression for survival probability and hazard ratios.

Main Results:

  • Children with advanced-stage CNS tumors were more likely to be under 1 year old, Hispanic, or in the lowest SES quartile.
  • Hispanic children had higher odds of presenting with advanced-stage disease compared to non-Hispanic white children (OR 1.56).
  • Survival probabilities were poorest for children aged 1-10 years, Hispanic patients, non-Hispanic black patients, and those in the lowest SES quartile.

Conclusions:

  • Racial and ethnic disparities are linked to advanced-stage disease presentation in pediatric CNS solid tumors.
  • Tumor behavior and disease stage at diagnosis are critical predictors of survival in this population.
  • Distance to care and SES did not significantly impact disease stage in adjusted analyses, but influenced survival outcomes.

Related Concept Videos

Treatment Resistant Cancers02:56

Treatment Resistant Cancers

Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
3.9K
Treatment Resistent Cancers02:56

Treatment Resistent Cancers

1.5K
Pharmacokinetics in Pediatric Patients: Drug Distribution01:17

Pharmacokinetics in Pediatric Patients: Drug Distribution

Drug distribution in the pediatric population exhibits unique challenges and considerations due to the physiological differences between children, particularly neonates and infants, and adults. A crucial aspect of pediatric pharmacology is understanding how these differences impact the pharmacokinetics of various drugs, necessitating age-specific dosing strategies to ensure efficacy and safety.Neonates and infants have a higher total body water content, ~75%–90% of their body weight,...
419
Pharmacokinetics in Pediatric Patients: Drug Metabolism01:24

Pharmacokinetics in Pediatric Patients: Drug Metabolism

In pediatric care, understanding the nuances of hepatic drug metabolism is crucial, as it significantly differs from that of adults. This divergence is primarily due to the developmental stage of drug-metabolizing enzymes, which affects how medications are processed in the body. In neonates, for instance, the activity of Phase I enzymes—critical for the initial breakdown of drugs—is markedly reduced, functioning at just 20–40% of the levels seen in adults. This reduction poses...
312
Tumor Progression02:07

Tumor Progression

Tumor progression is a phenomenon where the pre-formed tumor acquires successive mutations to become clinically more aggressive and malignant. In the 1950s, Foulds first described the stepwise progression of cancer cells through successive stages.
Colon cancer is one of the best-documented examples of tumor progression. Early mutation in the APC gene in colon cells causes a small growth on the colon wall called a polyp. With time, this polyp grows into a benign, pre-cancerous tumor. Further...
7.8K
Tumor Progression02:07

Tumor Progression

3.5K